MSH3

mutS homolog 3

Explore in graph →CI-GENE-00015159HGNC:7326 ENSG00000113318 NCBI 4437 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MSH3 K383fs1
7-Ethyl-10-Hydroxycamptothecin + OxaliplatinSubstitutes	Colon Carcinoma	Predictive	D	Supports Sensitivity Response	2	submitted	EID9089 To assess the effects of MSH3 status on chemosensitivity, MSH3-deficient and MSH3-proficient HCT116 cells were treated with oxaliplatin, SN-38 (irinotecan metabolite), and 5-FU. Parental MSH3-deficien… (full text at CIViC) PMID 23724141 · Park et al., 2013 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (71)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved71 cohort rows (showing 21, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Prostate Adenocarcinoma (TCGA, Firehose Legacy) prad_tcga	Prostate Adenocarcinoma	Ssm	8	499	1.6%

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.